TerminatedPhase 3ketamine
Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients
Sponsored by Hospira, now a wholly owned subsidiary of Pfizer
NCT ID
NCT00492388
Target Enrollment
2 participants
Start Date
2007-06
Est. Completion
2011-08
About This Study
To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.
Conditions Studied
Interventions
- •PMI-150 (intranasal ketamine)
- •placebo
Eligibility
Age:18 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * at least 18 years of age * Patients requiring around-the-clock opioids for pain due to cancer and with a history of experiencing episodes of breakthrough pain Exclusion Criteria: * under 18 years * non-cancer pain * allergy to ketamine
Study Locations (1)
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States